Sign inJoin free

Watch / Small Cap

Recce Pharmaceuticals combating global threats with US Army

29 Apr 20255:43

Recce Pharmaceuticals combating global threats with US Army

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

James Graham, CEO from Recce Pharmaceuticals (ASX:RCE) shares the company's latest collaboration with the US Army's Infectious Diseases Institute. This partnership focuses on developing solutions for both military and civilian pathogenic threats. It signifies a step forward in their antibacterial research.

Recce's (ASX:RCE) compound was well-received in phase two trials for burn wound infections, showcasing efficacy and tolerance. They now aim to further test their compound on significant pathogenic threats like anthrax and plague. If successful, this could lead to substantial commercial opportunities.

James mentions a positive strategic direction with ongoing projects for diabetic foot ulcers in Indonesia and other US government engagements. With recent shareholder interest boosting their financial position, Recce is poised to embrace major market opportunities, especially in the antibiotic sector.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy